香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，osemitamab聯合納武利尤單抗與CAPOX作 為胃或胃食管結合部腺癌(TranStar102)一線治療的I/II期臨床試驗(Transtar102)G 隊列基於CLDN18.2和PD-L1表達的更新療效分析。該研究結果以壁報形式（摘 要編號：#299P）亮相於在新加坡舉行的歐洲腫瘤內科學會亞洲年會(ESMO Asia Congress 2025)。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 自願公告 創勝醫藥於ESMO Asia公佈osemitamab三聯療法一線治療胃或胃食管 結合部腺癌的I/II期(Transtar102)更新療效數據 • 公佈數據表明，對於CLDN18.2較高表達患者，無論其PD-L1表達水平如何， 均取得了令人鼓舞的療效結果－中位無進展生存期 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 ...

Core Viewpoint - The chairman of the board, Qian Xueming, has increased his stake in Chuangsheng Group (06628) by purchasing 20,000 shares at a price of HKD 2.5 per share, totaling HKD 50,000, which indicates confidence in the company's future prospects [1] Summary by Category - **Shareholding Increase** - Qian Xueming acquired 20,000 shares of Chuangsheng Group at HKD 2.5 each, amounting to a total investment of HKD 50,000 [1] - Following this transaction, his total shareholding in the company has risen to 38.02 million shares, representing an ownership stake of 8.4% [1]

Core Viewpoint - The chairman of the board, Qian Xueming, increased his stake in Chuangsheng Group (06628) by purchasing 20,000 shares at a price of HKD 2.5 per share, totaling HKD 50,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Shareholding Activity** - Qian Xueming's latest shareholding after the purchase is 38.02 million shares, representing an ownership stake of 8.4% in Chuangsheng Group [1]

Group 1 - The company, 创胜集团-B (06628), announced the grant of 200,000 reward shares to one reward grantee under its share incentive plan [1] - Additionally, the company granted 800,000 stock options to two option grantees under the same share incentive plan [1]

Core Points - The company, 创胜集团-B (06628), announced the issuance of 200,000 reward shares to one reward grantee under its share incentive plan [1] - Additionally, the company granted 800,000 stock options to two option grantees under the same share incentive plan [1]

Group 1 - The company, 创胜集团-B (06628.HK), announced the grant of 200,000 reward shares to one reward grantee under its share incentive plan on November 20, 2025 [1] - Additionally, the company granted 800,000 stock options to two option grantees under the same share incentive plan [1]

根據上市規則第17.06A條，董事會宣佈，於2025年11月20日，本公司根據股份激 勵計劃向1名獎勵承授人授出200,000股獎勵股份（「11月獎勵授出」）及根據股份激 勵計劃向2名購股權承授人授出800,000份購股權（「11月購股權授出」）。 11月獎勵授出的詳情載列如下： 授出獎勵股份的購買價： 零 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 根據股份激勵計劃授出獎勵股份及購股權 股份於授出日期的收市價： 每股股份2.86港元 1 授出日期： 2025年11月20日 獎勵承授人人數： 1名服務提供商 授出獎勵股份數目： 200,000股獎勵股份（佔本公司截至本公告日期已 發行股本（不包括庫存股份）總額的約0.04%）授予 Marciniak先生，彼透過受聘為本公司顧問，從而成 為本公司的服務提供商，有 ...

Core Viewpoint - The chairman of the board, Qian Xueming, has increased his stake in Chuangsheng Group (06628) by purchasing 34,000 shares at a price of HKD 2.8581 per share, totaling approximately HKD 97,200, which indicates confidence in the company's future prospects [1] Summary by Category Shareholding Activity - Qian Xueming's recent purchase brings his total shareholding to 38 million shares, representing an ownership stake of 8.39% in Chuangsheng Group [1]

Core Viewpoint - The chairman of the board, Qian Xueming, increased his stake in Chuangsheng Group (06628) by purchasing 34,000 shares at a price of HKD 2.8581 per share, totaling approximately HKD 97,200, which indicates confidence in the company's future prospects [1] Summary by Category Shareholding Activity - Qian Xueming's recent purchase brings his total shareholding to 38 million shares, representing an ownership stake of 8.39% in Chuangsheng Group [1]